Funding for this research was provided by:
Suomen Lääketieteen Säätiö
Jane ja Aatos Erkon Säätiö
Väinö ja Laina Kiven Säätiö
Yrjö Jahnssonin Säätiö
the Finnish Society of Allergology and Immunology
State funding for university-level health research (TYH2019322)
Received: 13 December 2020
Accepted: 29 June 2021
First Online: 8 July 2021
: Approval for the study was obtained from the ethics committee at Tampere University Hospital (2/1996), and written consent was obtained from all subjects.
: Not applicable.
: STS reports a grant from GSK and consultancies for AstraZeneca, ERT, Novartis, Sanofi Pharma and Roche. SC reports personal fees from AstraZeneca, non-financial support from Boehringer Ingelheim, non-financial support from Actelion Pharmaceuticals, non-financial support from MSD, and non-financial support from Astellas. JK reports personal fees from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD, Mundipharma, Novartis, Orion Pharma, and Teva. JB reports personal fees and other fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, and Uriach and other fees from Kyomed INNOV. All these are outside the submitted work. All other authors declare no conflicts of interest.